Oxybutynin hydrochloride for managing neurogenic detrusor overactivity in people 6 years and over with spinal cord injury or spina bifida (terminated appraisal)

  • Technology appraisal
  • TA1154
  • Published: 
Download guidance (PDF)

Overview

NICE is unable to make a recommendation on oxybutynin hydrochloride (Vesoxx) for managing neurogenic detrusor overactivity. This is because the company did not provide an evidence submission.

Last reviewed: 07 May 2026

Next review: We will review this decision if the company decides to make a submission.

Guidance development process

How we develop NICE technology appraisal guidance